Modulators of Glutamatergic Signaling as Potential Treatments for Neuropsychiatric Disorders


Zoran M. Pavlovic, MD (Editor)
Worldwide Clinical Trials Inc., Mannheim, Germany

Series: Psychiatry – Theory, Applications and Treatments
BISAC: MED105000

Mounting evidence from preclinical and clinical research suggests that the glutamatergic system is highly involved in the pathophysiology of major neuropsychiatric disorders. All of these scientific activities are a necessary first step, which translates into opportunities in terms of development of new and improved treatment strategies. Glutamate-based research over the last couple of decades has provided novel insights into the pathogenesis of both psychiatric disorders such as treatment resistant depression, bipolar disorder, schizophrenia, PTSD, ADHD and neurological disorders including Alzheimer’s dementia, migraine, epilepsy, ALS and neuropathic pain.

Recent news developments also indicate glutamate involvement in neurodevelopmental disorders such as autism. In addition to the above, recent discoveries that several novel therapeutic agents like riluzole, memantine, ketamine, topiramate and lamotrigine possess glutamatergic properties as part of their mechanism of action, further boosted the interest of drug development companies and academic research centers to put more effort into investigating novel therapeutically efficacious compounds. Moreover, recent large “real life” clinical studies, such as STAR*D, also looked into disease-associated glutamate genetics and paved the way for the future creation of first individualized pharmacogenetic treatments.

The overall purpose of this book is to provide the reader with expert opinions relating to the most up-to-date information on glutamate’s role in pathophysiology of neuropsychiatric disorders and current and future glutamatergic treatment strategies. The authors’ hope that this contribution will foster future research activities, which are all ultimately aiming to improve quality of life in patients with chronic, psychiatric and neurological disorders, thus enhancing their contribution to society.
(Imprint: Nova Biomedical)

Table of Contents

Table of Contents


Chapter 1
Role of Glutamate in Aggression
(Cedo D. Miljevic, Ana Munjiza, Dusica Lecic Tosevski, Institute of Mental health, Belgrade, Serbia, and others)

Chapter 2
Should we be Excited about Glutamate Dysregulation in the Etiology of ADHD? A Review of the Data
(S.R. Batten, G.A. Gerhardt, P.E.A. Glaser, Department of Anatomy & Neurobiology, University of Kentucky, KY, USA, and others)

Chapter 3
Metabotropic Glutamate Receptors in Addictive Disorders
(Jeremy Egnatios and M. Foster Olive, School of Medicine, University of California at San Diego, La Jolla, CA, USA, and others)

Chapter 4
Migraine and Glutamate – Modulators of Glutamatergic Signalling as Potential Treatments of Neuropsychiatric Disorders
(C.F.Gasparini, R.A. Smith, and L.R. Griffiths, Menzies Health Institute Queensland, Griffith University Gold Coast, Southport, QLD, Australia, and others)

Chapter 5
Obsessive-Compulsive Disorder
(Gyula Bokor, Peter D. Anderson, Staff Psychiatrist, Taunton State Hospital, Taunton, MA, USA, and others)

Chapter 6
The Glutamatergic System in Alzheimer’s Disease Pathology
(S. Kar and G.B. Baker, Department of Medicine (Division of Neurology) and Centre for Prions and Protein Folding Diseases and Neurochemical Research Unit, Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada)

Chapter 7
Neurotransmission in Schizophrenia
(Marc C. Debelle, Medical Director, Clinical Development in several Pharmaceutical Companies, Brussels, Belgium)



“Glutamate is the single most common excitatory neurotransmitter in the human CNS and profoundly impacts on a number of brain circuits implicated in the production of mental disorders. Alterations in glutamatergic signaling are at the core of these symptoms, and in addition to NMDA hypofunction, disturbances in feedback loops are also present. Dr. Pavlovic’s book provides an overview on these and other clinically relevant issues that will help readers think through their practical and research implications for treatment and drug development. Particularly compelling are chapters that cover a myriad of common and important disease states, including attention-deficit hyperactivity disorder, obsessive-compulsive disorder, Alzheimer’s disease, migraine headache, addictive disorders, and clinical concerns that are encountered across different disorders such as aggression.” – Leslie Citrome, MD, MPH, Clinical Professor of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY USA. Editor in Chief, International Journal of Clinical Practice, Wiley-Blackwell, Oxford, UK

“It is clear that the glutamatergic system plays a critical role in modulating brain circuits that regulate core symptom domains across a range of neuropsychiatric conditions. As such, experimental therapeutic approaches to glutamate signalling have assumed increasing importance in academic and industry approaches to CNS drug development, and this book is a invaluable resource to guide such development in our field.” – Eric Hollander, MD, Director – Autism and Obsessive Compulsive Spectrum Program,and Anxiety and Depression Program,Clinical Professor of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine and Montefiore Medical Center

“A large body of both preclinical and clinical data points to the important role of the glutamate system in neuropsychiatric disorders. This volume represents a timely assessment of the involvement of the glutamate system in a range of psychiatric disorders and the therapeutic potential of agents targeting this system.” – John Dunlop Vice President and Head, Neuroscience Innovative Medicines at AstraZeneca

Click here to read the book review by – Prakash Masand, MD, Chairman and CEO, Global Medical Education

Click here to read the book review by – Raimund Buller, MD, Vice President, Global Clinical Research Psychiatry, Lundbeck, France

Click here to read the book review by – George Garibaldi, MD, VP CNS Development, F. Hoffmann-La Roche

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!